Finding suggests novel ways to boost vaccination or natural defensesJuly 08, 2008Our bodies rely on the production of potent, or 'high affinity', antibodies to fight infection. The process is very complex, yet Sydney scientists have discovered that it hinges on a single molecule, a growth factor, without which it cannot function. There is much we do not yet understand about our immune system. In simple terms, our bodies produce B cells, which make antibodies, and T cells, which help them. Ways in which these cells operate and interact with each other are still coming to light. Roughly eight years ago, a new subset of T cells, T follicular helper (TFH) cells, was identified. This important class of T cells operates in specific environments termed 'germinal centres', specialised areas within lymph organs where B cells proliferate to form high affinity antibodies whenever we fight infection. TFH cells play a critical role in that they communicate with, and help activate, B cells.
The novel finding made by Dr Cecile King and PhD student Alexis Vogelzang, from the Garvan Institute of Medical Research in Sydney, was that the molecule interleukin 21 (IL-21) is a growth factor for TFH cells. A paper detailing this finding was published online today in the prestigious international journal Immunity. A cytokine, or chemical messenger, IL-21 is already well known to immunologists. While its newly identified growth factor role is only one of several functions, that function is fundamental. Without IL-21, the all-important TFH cells could neither develop nor survive. Dr Cecile King, head of the Mucosal Autoimmunity Group at Garvan, has been investigating the roles of IL-21 for several years. "We already knew that IL-21 was produced by TFH cells and that it was a major initiator of proliferation in B cells," she said. "We were surprised to find that TFH cells not only produce IL-21, they also absolutely need it to survive and they utilise it to function." "We showed that if you take a mouse genetically deficient in IL-21 and immunise it, you don't get TFH cells and you don't get antibody production. Conversely, if you put IL-21 receptor sufficient, or normal, T cells into the same mouse, where of course the B cells remain abnormal, you recover the normal immune reaction." "These specialised T cells are thought to be the ones that direct traffic. They are the only ones that can move into the B cell zone and initiate high affinity antibody production." "Without IL-21, we probably wouldn't be completely immunodeficient, just severely compromised. In addition to the high affinity antibodies we're talking about, our bodies also produce a lot of low affinity antibodies for mopping up infection. That low level response happens around-the-clock and is one of our body's first lines of defence." "You could say that IL-21 directs the most finely-tuned aspect of our immune response. The highly specialised weaponry developed on-the-spot to target aggressive invaders." "This finding suggests novel ways to boost vaccination or natural defences." Research Australia Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size. Statin Microfluidic device Computer Model Medulloblastoma Mitochondria Stem Cell Academic Performance Pulmonary Embolism Brain Cancer MRI Drug Addiction Nitrous Oxide Heart Attack Emotions White Blood Cells Gene Expression Fingerprints Cancer Research Lyme Disease Flooding Vitamin B12 Fear Sea Turtles Air Pollution Brain Cells
See More: Science News Tags | |||||||||||||||||||||
|
Related Antibodies Current Events and Antibodies News Articles Gene expression findings a step toward better classification and treatment of juvenile arthritis Scientists have discovered gene expression differences that could lead to better ways to classify, predict outcome, and treat juvenile idiopathic arthritis (JIA). MIT: Extending the shelf life of antibody drugs A new computer model developed at MIT can help solve a problem that has plagued drug companies trying to develop promising new treatments made of antibodies: Such drugs have a relatively short shelf life because they tend to clump together, rendering them ineffective. Scripps research scientists find key culprits in lupus The more than 1.5 million Americans with systemic lupus erythematosus (or lupus) suffer from a variety of symptoms that flare and subside, often including painful or swollen joints, extreme fatigue, skin rashes, fever, and kidney problems. Ultrasensitive detector promises improved treatment of viral respiratory infections A Vanderbilt chemist and a biomedical engineer have teamed up to develop a respiratory virus detector that is sensitive enough to detect an infection at an early stage, takes only a few minutes to return a result and is simple enough to be performed in a pediatrician's office. Effective pain treatment for cancer patients? Cancer patients often suffer from severe pain that cannot be effectively treated with conventional medication. How to confirm the causes of iron deficiency anemia in young women Iron-deficiency anaemia (IDA) is commonly seen in women aged <50 years. The diagnostic workflow in young women affected by IDA is not clearly established. Structures from the human immune system's oldest branch shed light on a range of diseases How molecules of the oldest branch of the human immune system have interconnected has remained a mystery. Major Breakthrough in Early Detection and Prevention of AMD A team of researchers led by Dr. Jayakrishna Ambati at the University of Kentucky has discovered a biological marker for neovascular age-related macular degeneration (AMD), the leading cause of blindness in older adults. NIAID media availability: New strategy proposed for designing antibody-based HIV vaccine Most vaccines that protect against viruses generate infection-fighting proteins called antibodies that either block infection or help eliminate the virus before it can cause disease. Novel DNA vaccine leads to kidney damage prevention in systemic lupus erythematosus models DNA vaccination using lupus autoantigens and interleukin-10 (IL-10, a cytokine that plays an important role in regulating the immune system) has potential as a novel therapy to induce antigen specific tolerance and may help to prevent kidney damage in patients with systemic lupus erythematosus (SLE). More Antibodies Current Events and Antibodies News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||